Search Results

You searched for : Dapagliflozin  

Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach

Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline ...
Apr 04

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus

These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 ...
Oct 31

Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ...
Oct 16

Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ...
Oct 15

The Twin Therapy that Could Help Win India’s Fight Against Diabetes

As India continues its journey towards becoming the diabetes capital of the world, the medical fraternity faces the challenge of changing old habits both in ...
Oct 08

Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA

...
Apr 15

Glenmark Launches Zita DM: A Triple-Drug Combination for Type 2 Diabetes for just Rs 14

Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of ...
Oct 19

Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease

If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease...
Jun 28

Farxiga granted Priority Review in the US for the treatment of patients with chronic kidney disease

Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type-2 diabetes...
Jan 06

AstraZeneca advances leadership in renal disease with more than 80 abstracts at ASN Kidney Week 2020 Reimagined

For roxadustat, more than 40 abstracts present safety and efficacy outcomes in anaemia of chronic kidney disease ...
Oct 20

Forxiga recommended for approval in the EU by CHMP for heart failure

If approved, Forxiga would become the first SGLT2 inhibitor indicated for heart failure with reduced ejection fraction in patients with and without type-2 diabetes...
Oct 19

Zydus Healthcare launches highly affordable Dapagliflozin tablets in India for the treatment of Type 2 diabetes

Zydus Healthcare Limited announced that it is launching the anti-diabetic Dapagliflozin tablets in India upon its patent expiry under the brand name ‘Dapaglyn’...
Oct 05

Early-stage data on Astra Zeneca COVID vaccine due Monday: Lancet

Early-stage human trial data on a vaccine being developed by AstraZeneca and Oxford University will be published on July 20. ...
Jul 17

Glenmark Receives ANDA for Dapagliflozin and Saxagliptin Tablets

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. ...
Apr 30

Glenmark Receives Approval for Combination of Remogliflozin Etabonate and Metformin Hydrochloride for Adults With Type 2 Diabetes in India

Earlier in April 2019, Glenmark received regulatory approval for Remogliflozin etabonate in India and became the first company in the world to launch Remogliflozin with ...
Sep 14

15 Matching result(s) found!

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026